<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733185</url>
  </required_header>
  <id_info>
    <org_study_id>AT009149-01</org_study_id>
    <secondary_id>UH3AT009149</secondary_id>
    <nct_id>NCT02733185</nct_id>
  </id_info>
  <brief_title>Trial to Assess Chelation Therapy 2</brief_title>
  <acronym>TACT2</acronym>
  <official_title>Trial to Assess Chelation Therapy 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mt. Sinai Medical Center, Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mt. Sinai Medical Center, Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled
      factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and
      minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial
      infarction (MI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of TACT2, therefore, is to determine if the chelation-based strategy
      increases the time to the first occurrence of any of the components of the TACT2 primary
      endpoint: all-cause mortality, myocardial infarction, stroke, coronary revascularization, or
      hospitalization for unstable angina compared to the placebo chelation strategy.

      TACT2 is a 2x2 factorial trial testing 40-weekly edetate disodium-based chelation infusions
      and twice daily high-dose oral multivitamins and multiminerals (OMVM) in a placebo-controlled
      design.

      TACT2 is being carried out to replicate the findings of TACT1, which found a striking
      reduction of recurrent cardiovascular events in post-MI diabetic patients receiving edetate
      disodium-based chelation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19
  </why_stopped>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Diabetes</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Active/Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active/Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/ Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>disodium EDTA</intervention_name>
    <arm_group_label>Active/Active</arm_group_label>
    <arm_group_label>Active/Placebo</arm_group_label>
    <other_name>EDTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Multi Vitamins/Minerals (OMVM)</intervention_name>
    <arm_group_label>Active/Active</arm_group_label>
    <arm_group_label>Placebo/ Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo disodium EDTA</intervention_name>
    <arm_group_label>Placebo/ Active</arm_group_label>
    <arm_group_label>Placebo/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Oral Multi Vitamins/Minerals (OMVM)</intervention_name>
    <arm_group_label>Placebo/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: â‰¥ 50 years

          2. History of diabetes, defined as medical record evidence or patient report of currently
             using insulin or oral hypoglycemic agents, or with a history of fasting blood glucose
             measurement of 126 mg/dL or higher, or a history of HbA1c of 6.5% or higher.

          3. History of myocardial infarction based on the Universal Definition of MI.

               1. When information about the MI hospitalization is available, all MI types except
                  Type 2 qualify for study entry.

               2. When information about the MI hospitalization is not available, a wall motion
                  abnormality on imaging or a perfusion defect on scan that corresponds to a
                  coronary distribution, whether or not accompanied by pathological Q waves in the
                  appropriate distribution, will qualify the patient for study entry. This
                  criterion requires a call to the CCC for case review.

        Exclusion Criteria:

          1. Baseline serum creatinine &gt;2.0 mg/dL.

          2. HbA1C &gt;11%.

          3. Myocardial infarction within 6 weeks of randomization.

          4. History of allergic reactions to EDTA or any other components of the chelation
             solution, including heparin. Site personnel are to call the CCC to discuss heparin
             allergy.

          5. Coronary or peripheral arterial revascularization procedure performed within the last
             6 months.

          6. Planned revascularization procedure in the 6 months following enrollment.

          7. Heart failure hospitalization within 6 months prior to enrollment or in clinical heart
             failure at the time of proposed enrollment (such as NYHA Class 3 dyspnea + rales
             &gt;basilar, and additional signs of fluid overload). Such patients may be treated with
             diuretics and enrolled when stable.

          8. Poor or no venous access in the upper extremities.

          9. a. Prior intravenous chelation therapy consisting of &gt; 1 infusion within 5 years; if
             only 1 infusion took place, patient cannot be enrolled for at least 12 months after
             said infusion.

             b. Oral chelation therapy with an approved oral chelating agent within 2 years.

         10. Prior participation in TACT.

         11. Baseline platelet count &lt;100,000.

         12. History of cigarette smoking within the last 3 months.

         13. ALT or AST &gt; 2.0 times the upper limit of normal.

         14. Wilson's disease, hemochromatosis, or parathyroid disease.

         15. Any medical condition including a current diagnosis of cancer (except non-melanoma
             skin cancer) that will limit patient survival over the duration of the trial.

         16. Any factor that suggests that the potential participant will not be able to adhere to
             the protocol.

         17. Women of child-bearing potential including those with plans for post-menopausal in
             vitro fertilization or other reproductive technology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gervasio A Lamas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Sinai Medical Center of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin J Anstrom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University (Duke Clinical Research Institute)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel B Mark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University (Duke Clinical Research Institute)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107.</citation>
    <PMID>23532240</PMID>
  </reference>
  <reference>
    <citation>Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15-24. doi: 10.1161/CIRCOUTCOMES.113.000663. Epub 2013 Nov 19.</citation>
    <PMID>24254885</PMID>
  </reference>
  <reference>
    <citation>Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2.</citation>
    <PMID>24952858</PMID>
  </reference>
  <reference>
    <citation>Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002.</citation>
    <PMID>22172430</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mt. Sinai Medical Center, Miami</investigator_affiliation>
    <investigator_full_name>Gervasio Lamas, MD</investigator_full_name>
    <investigator_title>TACT2 Study Chair</investigator_title>
  </responsible_party>
  <keyword>chelation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

